Research – grade capsule formulation supplied in a sealed bottle. BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment, studied in controlled laboratory settings for its relationship to tissue repair, angiogenesis, gastrointestinal cytoprotection, inflammatory signaling, and neuroprotection-focused cellular pathways.
BPC-157 is a partial sequence of a 40 kDa human gastric juice protein originally identified by Sikirić and colleagues in the early 1990s. In contrast to most regenerative peptides, it shows oral bioavailability and remarkable stability in gastric acid — properties consistent with its physiological origin in the stomach. The peptide has been characterized in tendon, ligament, muscle, gut, vascular, neural and bone injury models, where it consistently accelerates structural recovery, restores barrier function and rescues vascular perfusion through a coordinated upregulation of growth factor receptors, the nitric oxide system and angiogenic signaling. Recent mechanistic work has implicated formation of new vasculature (“salvage of the venous system”) as a unifying mechanism across organ systems. With a benign safety profile through six-month rodent toxicology and toxicology already taken to Phase II clinical evaluation in inflammatory bowel disease (PL 14736), BPC-157 stands as one of the few “research peptides” with a genuinely deep, reproducible evidence base.
